Skip to main content

Table 2 Antidiabetic Drug use, by trimester, in the cohort of all livebirth pregnancies during 2001–2013 in the MSDD

From: Use of Antidiabetic drugs during pregnancy among U.S. women with Livebirth deliveries in the Mini-Sentinel system

 Use in the 90 Days Before PregnancyAny Use During PregnancyAny Use, First TrimesterAny Use, Second TrimesterAny Use, Third Trimester
Total unique pregnancies1,895,604 (100%)1,895,604 (100%)1,895,604 (100%)1,895,604 (100%)1,895,122 (100%)
Drug Class or Product
 Use of Any Drug38,017 (2.0%)82,676 (4.4%)40,013 (2.1%)35,587 (1.9%)63,483 (3.4%)
 Alpha-Glucosidase Inhibitors21 (<0.1%)149 (<0.1%)19 (< 0.1%)24 (<0.1%)129 (<0.1%)
 Amylin Analog55 (<0.1%)48 (<0.1%)46 (<0.1%)9 (< 0.1%)5 (< 0.1%)
 Metformin30,194 (1.6%)32,757 (1.7%)29,431 (1.6%)15,827 (0.8%)9897 (0.5%)
 Dipeptidyl Peptidase-4 Inhibitors226 (< 0.1%)242 (< 0.1%)227 (< 0.1%)87 (< 0.1%)50 (< 0.1%)
 Glucagon-like Peptide-1 Agonists403 (<0.1%)333 (<0.1%)316 (<0.1%)77 (<0.1%)32 (<0.1%)
 Meglitinide Analogs45 (<0.1%)44 (<0.1%)43 (<0.1%)12 (<0.1%)2 (<0.1%)
 Sulfonylureas – Use of Any Drug2018 (0.1%)28,240 (1.5%)2748 (0.1%)6325 (0.3%)26,234 (1.4%)
  Glimepiride312 (<0.1%)280 (<0.1%)255 (<0.1%)97 (<0.1%)61 (<0.1%)
  Glipizide675 (<0.1%)768 (< 0.1%)617 (<0.1%)316 (<0.1%)218 (<0.1%)
  Glyburide976 (0.1%)27,269 (1.4%)1868 (0.1%)5905 (0.3%)25,973 (1.4%)
  Tolazamide80 (<0.1%)82 (<0.1%)82 (<0.1%)53 (<0.1%)23 (<0.1%)
 Thiazolidinediones965 (0.1%)874 (0.1%)841 (<0.1%)274 (<0.1%)123 (<0.1%)
 Combination Products565 (<0.1%)633 (<0.1%)520 (<0.1%)204 (<0.1%)155 (<0.1%)
 Insulin – Any Injectable Insulin7351 (0.4%)34,476 (1.8%)12,289 (0.7%)18,028 (0.9%)33,447 (1.8%)
  Rapid-acting5842 (0.3%)25,959 (1.4%)10,074 (0.5%)14,602 (0.8%)24,705 (1.3%)
  Intermediate-acting1803 (0.1%)26,103 (1.4%)6607 (0.4%)11,824 (0.6%)24,745 (1.3%)
  Long-acting2394 (0.1%)4834 (0.3%)2846 (0.2%)2791 (0.2%)3436 (0.2%)
  Other-acting598 (<0.1%)1556 (0.1%)854 (0.1%)794 (0.1%)976 (0.1%)